NCT02492867View on ClinicalTrials.gov

A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer

NACompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

January 14, 2016

Primary Completion Date

November 28, 2021

Study Completion Date

April 21, 2022

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
RADIATION

Response-driven Adaptive Radiation Therapy

DRUG

Carboplatin

AUC 2 concurrent with RT; AUC 6 during consolidation. Given IV

DRUG

Paclitaxel

40 mg/m\^2 IV concurrent with RT; 200 mg/m\^2 during consolidation. Given IV

DEVICE

FDG-PET

DEVICE

V/Q SPECT

DRUG

Durvalumab

10 mg/kg during consolidation. Given IV

Trial Locations (2)

48105

VA Ann Arbor Healthcare System, Ann Arbor

48109

University of Michigan Cancer Center, Ann Arbor

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Michigan Rogel Cancer Center

OTHER

NCT02492867 - A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter